Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geraint Davies

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Clinical Pharmacology and Therapeutics|December 17, 2025
Improving Genotype Imputation in High-Dimensional Pharmacogenomics Using Multiple Imputation: Evaluation with Machine Learning ApproachesInnocent G Asiimwe, Tao You, Daniel F Carr, et al.
Plos Medicine|September 21, 2020
STrengthening the Reporting Of Pharmacogenetic Studies: Development of the STROPS guidelineMarty Chaplin, Jamie J Kirkham, Kerry Dwan, et al.
BMJ Open|July 14, 2019
Protocol for the development of the STrengthening the Reporting Of Pharmacogenetic Studies (STROPS) guideline: checklist of items for reporting pharmacogenetic studiesMarty Richardson, Jamie J Kirkham, Kerry M Dwan, et al.
Pharmacotherapy|March 2, 2016
Adequacy of Rifampin Absorption after Jejunostomy Tube AdministrationKatharine E Stott, Bhagteshwar Singh, Mike B J Beadsworth, et al.
Eclinicalmedicine|October 17, 2024
Efficacy and safety of higher dose rifampicin in adults with presumed drug-susceptible tuberculosis: an updated systematic review and meta-analysisKathryn A Haigh, Hussein H Twabi, Linda Boloko, et al.
The Lancet. Global Health|March 18, 2022
Social and health factors associated with adverse treatment outcomes among people with multidrug-resistant tuberculosis in Sierra Leone: a national, retrospective cohort studyRashidatu Fouad Kamara, Matthew J Saunders, Foday Sahr, et al.
Antimicrobial Agents and Chemotherapy|May 25, 2016
Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse ModelYanmin Hu, Henry Pertinez, Fatima Ortega-Muro, et al.
The Journal of Antimicrobial Chemotherapy|December 16, 2017
Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteriaYingjun Liu, Henry Pertinez, Fatima Ortega-Muro, et al.
The Journal of Antimicrobial Chemotherapy|March 31, 2009
Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteersLaura Dickinson, Marta Boffito, David Back, et al.
Antimicrobial Agents and Chemotherapy|September 19, 2019
Re-growth of <i>Mycobacterium tuberculosis</i> populations exposed to antibiotic combinations is due to the presence of isoniazid and not bacterial growth rateCharlotte L Hendon-Dunn, Henry Pertinez, Alice A N Marriott, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Clinical Pharmacology and Therapeutics|December 17, 2025
Improving Genotype Imputation in High-Dimensional Pharmacogenomics Using Multiple Imputation: Evaluation with Machine Learning ApproachesInnocent G Asiimwe, Tao You, Daniel F Carr, et al.
Plos Medicine|September 21, 2020
STrengthening the Reporting Of Pharmacogenetic Studies: Development of the STROPS guidelineMarty Chaplin, Jamie J Kirkham, Kerry Dwan, et al.
BMJ Open|July 14, 2019
Protocol for the development of the STrengthening the Reporting Of Pharmacogenetic Studies (STROPS) guideline: checklist of items for reporting pharmacogenetic studiesMarty Richardson, Jamie J Kirkham, Kerry M Dwan, et al.
Pharmacotherapy|March 2, 2016
Adequacy of Rifampin Absorption after Jejunostomy Tube AdministrationKatharine E Stott, Bhagteshwar Singh, Mike B J Beadsworth, et al.
Eclinicalmedicine|October 17, 2024
Efficacy and safety of higher dose rifampicin in adults with presumed drug-susceptible tuberculosis: an updated systematic review and meta-analysisKathryn A Haigh, Hussein H Twabi, Linda Boloko, et al.
The Lancet. Global Health|March 18, 2022
Social and health factors associated with adverse treatment outcomes among people with multidrug-resistant tuberculosis in Sierra Leone: a national, retrospective cohort studyRashidatu Fouad Kamara, Matthew J Saunders, Foday Sahr, et al.
Antimicrobial Agents and Chemotherapy|May 25, 2016
Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse ModelYanmin Hu, Henry Pertinez, Fatima Ortega-Muro, et al.
The Journal of Antimicrobial Chemotherapy|December 16, 2017
Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteriaYingjun Liu, Henry Pertinez, Fatima Ortega-Muro, et al.
The Journal of Antimicrobial Chemotherapy|March 31, 2009
Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteersLaura Dickinson, Marta Boffito, David Back, et al.
Antimicrobial Agents and Chemotherapy|September 19, 2019
Re-growth of <i>Mycobacterium tuberculosis</i> populations exposed to antibiotic combinations is due to the presence of isoniazid and not bacterial growth rateCharlotte L Hendon-Dunn, Henry Pertinez, Alice A N Marriott, et al.
Pageof 4